RxDoctor Payments DataLook up a doctor →

Sammy Khatib, MD

Clinical Cardiac Electrophysiology · New Orleans, LANPI 1154491819

Payments from drug & device makers

$290,246in general payments, 2019–2025

Across 502 payments — averaging $578.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$260K
  • Biotronik Inc.$20K
  • Medtronic$5K
  • Boston Scientific$1K
  • Volta Medical Inc$1K
  • Kestra Medical Technology Services, Inc.$538
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$19,85017%
  • Speaking & faculty fees$58,00050%
  • Travel & lodging$13,45112%
  • Food & beverage$23,46620%
  • Education$700%
  • Entertainment$1090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$290,246 in reported general payments places this provider in the 95th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.

See all clinical cardiac electrophysiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$115,116
Medicare patients
321
Services billed
1,299

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban682$698,903
XareltoRivaroxaban111$123,057
MultaqDronedarone Hcl60$89,612
Propafenone Hcl ErPropafenone Hcl23$5,912
Dofetilide23$5,818
Verapamil SrVerapamil Hcl39$4,398
Metoprolol Succinate300$4,303
Flecainide Acetate108$4,105
Amiodarone Hcl167$3,077
Dabigatran EtexilateDabigatran Etexilate Mesylate11$2,981
Verapamil ErVerapamil Hcl43$1,388
Diltiazem 24hr Er (Cd)Diltiazem Hcl55$1,106
Warfarin Sodium113$970
Diltiazem 24hr ErDiltiazem Hcl12$679
Carvedilol81$604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$88$698,903682 claims
Johnson & JohnsonXarelto$509$123,057111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 clinical cardiac electrophysiology providers in Louisiana.

Other clinical cardiac electrophysiology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →